EU rejects Eisai's Alzheimer's drug, causing shares to plummet in Japan and US

From Investing.com: 2024-07-28 22:30:38

Shares of Eisai plummeted 11% in Japan as EU regulators rejected Leqembi for early Alzheimer’s. Rejection due to risk of brain swelling. Re-examination sought by Eisai and Biogen. Potential 20% sales cut without EU approval. Eisai shares down to 5,890 yen, biggest drop since 2021. US sales may be impacted. Biogen shares down 7% in US trading. Leqembi, known as lecanemab, approved in other countries but not in Europe.



Read more at Investing.com: Shares of Japan’s Eisai tumble after EU rejects Alzheimer’s drug By Reuters